Financial Instruments - Schedule of Reconciliation of Contingent Consideration (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 4 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|---|---|
Jul. 31, 2026 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|
| Contingent Consideration | ||||||
| Change in valuation | $ 13,738 | $ 2,390 | ||||
| Ascyrus Medical LLC | ||||||
| Contingent Consideration | ||||||
| PMA approval payment | $ (25,000) | |||||
| Change in valuation | $ 1,100 | $ 2,600 | 10,800 | $ 2,400 | ||
| Ascyrus Medical LLC | Level 3 | ||||||
| Contingent Consideration | ||||||
| Balance as of December 31, 2025 | 60,580 | |||||
| PMA approval payment | (25,000) | |||||
| Change in valuation | 10,840 | |||||
| Balance as of September 30, 2026 | 46,420 | $ 46,420 | 46,420 | |||
| Endospan | ||||||
| Contingent Consideration | ||||||
| Change in valuation | (4,400) | |||||
| Endospan | Level 3 | ||||||
| Contingent Consideration | ||||||
| Balance as of December 31, 2025 | 0 | |||||
| Initial value | 21,782 | |||||
| Change in valuation | 2,898 | |||||
| Balance as of September 30, 2026 | $ 24,680 | $ 24,680 | $ 24,680 | |||